Difference between revisions of "Classification of urothelial carcinoma by immunohistochemistry"

A '''classification of [[urothelial carcinoma]] by immunohistochemistry''' can be done with three [[immunostains]].<ref name=pmid34103388 >{{cite journal |vauthors=Olkhov-Mitsel E, Hodgson A, Liu SK, Vesprini D, Xu B, Downes MR |title=Three-antibody classifier for muscle invasive urothelial carcinoma and its correlation with p53 expression |journal=J Clin Pathol |volume= |issue= |pages= |date=June 2021 |pmid=34103388 |doi=10.1136/jclinpath-2021-207573 |url=}}</ref>

*A large meta-analysis showed two markers (CK5/6, GATA3) can subclassify ~90% of urothelial carcinoma into prognostic groups.<ref>{{cite journal |vauthors=Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B |title=Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use |journal=EBioMedicine |volume=12 |issue= |pages=105–117 |date=October 2016 |pmid=27612592 |pmc=5078592 |doi=10.1016/j.ebiom.2016.08.036 |url=}}</ref>